BIBW 2992
Phase 3Small molecule
Boehringer IngelheimBIBW 2992 is one of 306 small molecule programs targeting Adenocarcinoma. It is currently in Phase 3.
9
Indications
48
Total Trials
0
Active Trials
305
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1BIBW 2992
Boehringer IngelheimPhase 3
Tecentriq
RochePreclinical
Trodelvy
GileadPreclinical
Halaven
EisaiPreclinical
Tykerb
GSKPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer7 trials
Show 4 more trials
Patients With Advanced Solid Tumors6 trials
Breast Cancer6 trials
Show 3 more trials
Advanced Solid Tumours5 trials
21 more indications
Prostate Cancer2 trials
EGFR Activating Mutation1 trial
Relapsed or Refractory1 trial
Malignant Glioma1 trial
EGFR Mutation1 trial
Metastatic Colorectal Cancer1 trial
Adenocarcinoma1 trial
Phase II1 trial
Trial1 trial
Bronchitis1 trial
Age1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BIBW 2992. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company